The global leader in carbon monoxide therapeutics
Proterris is a clinical development stage company focused on therapeutic applications of low-dose carbon monoxide. The company is based on groundbreaking scientific research led by Augustine M.K. Choi, MD, Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University, and David J. Pinsky, MD, J. Griswold Ruth M.D. & Margery Hopkins Ruth Professor of Internal Medicine, Professor of Molecular and Integrative Physiology, Chief of Cardiovascular Medicine and Scientific Director of the University of Michigan’s Cardiovascular Center, who, between them and Proterris, have generated an important body of clinical, translational and mechanistic research data, as well as a considerable intellectual property portfolio. Leveraging carbon monoxide’s (CO) demonstrated anti-fibrotic, anti-inflammatory and cytoprotective properties, Proterris initially focused on developing CO therapies for delayed graft function (DGF) in renal transplant recipients and idiopathic pulmonary fibrosis (IPF). Other indications (pulmonary arterial hypertension and acute respiratory distress syndrome) are also being developed by the National Institute of Health (NIH). In short, CO has enormous potential to significantly impact the lives of millions of patients suffering from a wide range of acute and chronic diseases.
Jeffrey Wager, M.D., Chairman & CEO; Augustine Choi, M.D., Scientific Co-Founder; Stephen and Suzanne Weiss Dean, Weill Cornell Medical School
Provost for Medical Affairs, Cornell Univ.; David Pinsky, M.D., Scientific Co-Founder; Chief of Cardiovascular Medicine & Scientific Director of Cardiovascular Center, University of Michigan; Joseph Wager, VP Business Development; Benjamin Perrone, Ph.D., Sr. Mgr Business Development
Portugal Ventures’ Investment Manager